Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HBV-MPL vaccine (208129)
HBV-MPL vaccine · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Group C | EXPERIMENTAL | - |
| Group D | EXPERIMENTAL | - |
| Group E | EXPERIMENTAL | - |
| Group F | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| HBV-MPL vaccine | BIOLOGICAL | 3-dose intramuscular injection |
| Engerix™-B | BIOLOGICAL | 3-dose intramuscular injection |
Inclusion Criteria: * Age: 50 to 70 years old. * Good physical condition as established by clinical examination and history taking at the time of entry. * Female participants who are at risk to become pregnant will be on a contraceptive programme if necessary during the study period. * Written info...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
The HBV-MPL vaccine is an investigational vaccine being developed for the prevention of Hepatitis B. It is designed to be given to adults, including older adults aged 50 years and above, and has been studied in healthy volunteers across several countries. It remains in clinical development and is not an approved product.
The HBV-MPL vaccine is being developed by GSK plc, which trades under the ticker GSK. GSK conducted the clinical program evaluating different formulations of the vaccine against its licensed Hepatitis B vaccine Engerix-B as the active comparator.
The HBV-MPL vaccine has reached Phase 3 clinical development. Three trials have been completed, including one Phase 3 study and two Phase 2 studies, with a combined enrollment of 703 participants. The vaccine is investigational and has not been approved for use.
The HBV-MPL vaccine has been evaluated in three completed trials: NCT00698906, a Phase 2 study in Austria with 160 adults aged 19 to 40; NCT00698555, a Phase 2 study in Belgium with 163 adults aged 18 to 40; and NCT00696891, a Phase 3 study in Belgium, Canada and Sweden with 380 adults aged 50 and older.
Yes, HBV-MPL vaccine (208129) is another name used for the HBV-MPL vaccine. Both names refer to the same GSK investigational Hepatitis B vaccine candidate, so searches using either term point to the same development program.
The trials were randomized and active controlled, comparing different formulations of the HBV-MPL vaccine against Engerix-B, GSK's licensed Hepatitis B vaccine. The studies enrolled healthy adult volunteers and assessed immunogenicity, reactogenicity and safety. All three trials have been completed.